View Older Stories View More Recent Stories
-
Roth Affirms Regeneron (REGN) at 'Buy' Following Q4 Results; Sees Opportunity in Shares on Pullback
-
Mast Therapeutics (MSTX) Prices 29M Offering of Common Stock and Warrants at $0.275/Unit
-
Mast Therapeutics Announces Pricing Of Underwritten Public Offering
-
Roth Capital Partners' Joe Reagor Interviewed by The Gold Report
-
Roth Capital Starts Denison Mines (DNN) at Buy
-
Roth Capital Downgrades SolarCity (SCTY) to Neutral; Sidelined Until Better Execution Appears
-
Mast Therapeutics (MSTX) to Offer Common Stock And Warrants
-
Mast Therapeutics Announces Proposed Public Offering Of Common Stock And Warrants
-
Roth Capital Downgrades Outerwall Inc. (OUTR) to Sell
-
Roth Capital Restarts Capstone Turbine (CPST) at Neutral; PT Moves to $1.60
-
Roth Capital Starts Heritage-Crystal Clean (HCCI) at Buy
-
Results from Cytori's (CYTX) Cell Therapy in ED with RP are 'Promising' - Roth Capital
-
Notable Analyst Rating Changes 2/3: (NPTN) (MNK) (SYNT) Upgraded; (MCHP) (XEL) (MS) Downgraded
-
Roth Capital Restarts Hydrogenics (HYGS) at 'Buy'; Sees Profitability by End of 2016
-
Roth Capital Restarts Plug Power (PLUG) at Neutral; New Air-Cooled Stack to Remain Key in 2016
-
Roth Capital Tranfers Coverage on Ballard Power (BLDP); Reaffirms at 'Buy,' PT of $2
-
Robertson Stephens Expands Investment Management Group, Robertson Stephens Partners LLC
-
Roth Affirms Flex Pharma (FLKS) at 'Buy' Following Positive NLC POC Data
-
Roth Capital Starts Mellanox Technologies (MLNX) at Buy
-
Streetinsider.com's Hot Lunchtime Reads 2/1: (JPM) (CSIQ) (BABA) (AAPL)
-
Canadian Solar (CSIQ) has Attractive Risk-Reward Below pre-ITC Extension Levels - Roth Capital
-
Current Valuation on Aduro Biotech (ADRO) Doesn't Appreciate Upcoming Opportunities - Roth Capital
-
Roth Capital Downgrades Outerwall Inc. (OUTR) to Neutral
-
Tearlab (TEAR) to Offer $15M in Common Stock
-
TearLab Announces Proposed Public Offering of Common Stock
-
8point3 Energy (CAFD) is Built to Last; Roth Affirms at 'Buy'
-
Roth Affirms SolarCity (SCTY) at 'Buy' as CPUC Passes NEM 2.0
-
Initial Read of Revised NEM PD Better than Expected; Roth Affirms SolarCity (SCTY) at 'Buy'
-
NEM 2.0 Decision Key for SolarCity (SCTY), But Risk-Reward Becoming Favorable - Roth
-
Roth Capital Starts First Solar (FSLR) at Buy
-
Aqua Metals Issues Annual Letter to Shareholders
-
Roth Reiterates Ligand Pharma (LGND) at 'Buy' Following Additional Kyprolis Approval
-
Roth Capital Remains Positive on Peregrine Pharma (PPHM) for 2016; Reaffirms at 'Buy'
-
Streetinsider.com's Hot Lunchtime Reads 1/19: (CMG) (ADMS) (TSLA) (SUNE)
-
Roth Capital Remains Confident on 2016 Thesis for Cytokinetics (CYTK) Following Recent Mgmt Meetings
-
Roth Capital Upgrades Regeneron Pharma (REGN) to Buy
-
Global Water Resources, Inc. Announces Filing of Registration Statement with the SEC
-
The PIPEs Report Sees Second Largest Year for Small-Cap Equity Financing Capital Since 2001
-
Roth Capital Says MeetMe's (MEET) Weakness is Related to Selling From Large Legacy Shareholder - Reiterates Buy
-
Streetinsider.com's Hot Lunchtime Reads 1/13: (ESRX) (MSFT) (AAPL) (LGND)
-
Roth Capital Impressed by Speed of Ligand (LGND) Capitalizing on OMT Acquisition; Affirms at 'Buy'
-
PlacementTracker Publishes 2015 PIPE Market League Tables
-
Roth Positive on BioLineRx (BLRX) and Merck's BL-8040 + KEYTRUDA Collaboration
-
Roth Capital Cuts PT Due to Natus Medical's (BABY) Light 2016 Outlook Following Venezuela Contract Delay
-
Roth Capital Slashes PT on Skullcandy (SKUL) to $5.50; Move to Wireless Could Still Pressure Shares
-
Low Production at Rochester Offset Results for Coeur Mining's (CDE) 4Q - Roth Capital Cuts PT to $6
-
Eilers Research Announces Name Change to “Eilers & Krejcik Gaming, LLC”
-
Highpower Special Committee Engages Financial Advisor and Legal Counsel
-
Roth Capital Cuts Price Target on Synergy Resources (SYRG) to $13 Following 1Q Results
-
Roth Capital Still Values Flamel Technologies (FLML) Following Revisions - Cuts PT to $17.50
